Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CBLB | Q13191 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16848813 | 0.85 | DYRK1A (0.41) | DYRK1AMETSCN5ATGFBR1PRKAB2 | |
| SCHEMBL5872614 | 0.81 | KCNH2 (0.51) | DYRK1AMETSCN5ATGFBR1 | |
| SCHEMBL2177217 | 0.81 | DYRK1A (0.47) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL23529908 | 0.81 | DYRK1A (0.44) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL3347070 | 0.81 | DYRK1A (0.44) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL21167757 | 0.80 | DYRK1A (0.41) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL7481486 | 0.80 | DYRK1A (0.41) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL3347107 | 0.77 | DYRK1A (0.41) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL23869389 | 0.75 | DYRK1A (0.43) | DYRK1AMETSCN5ATGFBR1PCSK9 | |
| SCHEMBL3346732 | 0.74 | DYRK1A (0.36) | DYRK1AMETSCN5ATGFBR1PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20210070751-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-11 | — | — | US | disclosed |
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2016133838-A1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781215-B2 | Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | TYK2, IL2, IL23R | DYRK1A 61/4885MET 2654/4885SCN5A 4355/4885 |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | DYRK1A 3380/4885MET 2809/4885SCN5A 3241/4885 |
| US-20190322672-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNG | DYRK1A 69/4885MET 2869/4885SCN5A 3964/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | DYRK1A 3616/4885MET 4165/4885SCN5A 1822/4885 |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | DYRK1A 3491/4885MET 313/4885SCN5A 3871/4885 |
| US-20210070751-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | TLR7, TLR8, TLR1 | DYRK1A 2190/4885MET 3112/4885SCN5A 2211/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | DYRK1A 2190/4885MET 3112/4885SCN5A 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.